JP2023501388A5 - - Google Patents

Info

Publication number
JP2023501388A5
JP2023501388A5 JP2022526138A JP2022526138A JP2023501388A5 JP 2023501388 A5 JP2023501388 A5 JP 2023501388A5 JP 2022526138 A JP2022526138 A JP 2022526138A JP 2022526138 A JP2022526138 A JP 2022526138A JP 2023501388 A5 JP2023501388 A5 JP 2023501388A5
Authority
JP
Japan
Prior art keywords
cell
cells
gene
sequence
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059730 external-priority patent/WO2021092581A1/en
Publication of JP2023501388A publication Critical patent/JP2023501388A/ja
Publication of JP2023501388A5 publication Critical patent/JP2023501388A5/ja
Pending legal-status Critical Current

Links

JP2022526138A 2019-11-08 2020-11-09 操作された制御性ｔ細胞の生成 Pending JP2023501388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933252P 2019-11-08 2019-11-08
US62/933,252 2019-11-08
PCT/US2020/059730 WO2021092581A1 (en) 2019-11-08 2020-11-09 Generation of engineered regulatory t cells

Publications (2)

Publication Number Publication Date
JP2023501388A JP2023501388A (ja) 2023-01-18
JP2023501388A5 true JP2023501388A5 (https=) 2023-11-16

Family

ID=73695146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526138A Pending JP2023501388A (ja) 2019-11-08 2020-11-09 操作された制御性ｔ細胞の生成

Country Status (9)

Country Link
US (1) US20220380727A1 (https=)
EP (1) EP4055039A1 (https=)
JP (1) JP2023501388A (https=)
KR (1) KR20220095223A (https=)
CN (1) CN114710958A (https=)
AU (1) AU2020378228A1 (https=)
CA (1) CA3160113A1 (https=)
IL (1) IL292676A (https=)
WO (1) WO2021092581A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323921A (zh) * 2020-10-28 2023-06-23 桑格摩生物治疗股份有限公司 从人多能干细胞生成cd4+效应t细胞和调节性t细胞
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
AU2022349176A1 (en) 2021-09-27 2024-04-11 Kyoto University Method for producing t cell
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
EP4600352A1 (en) 2022-09-26 2025-08-13 Kyoto University T cell production method
US20250270583A1 (en) * 2022-10-26 2025-08-28 Biodrive, Inc. Methods for Suppression of Gene Silencing in Plants
WO2024145653A2 (en) * 2022-12-30 2024-07-04 Bluerock Therapeutics Lp Engineered cells for the production of cd4+ t cells and cd4+ tregs
GB202312699D0 (en) * 2023-08-18 2023-10-04 Cambridge Entpr Ltd Controllable expression in mammalian cells
WO2025223995A1 (en) * 2024-04-26 2025-10-30 Tcbalance Biopharmaceuticals Gmbh Gene-modified t regulatory cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2017062035A1 (en) * 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
CA3091491A1 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of human foxp3 in gene edited t cells
AU2019261438B2 (en) 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells

Similar Documents

Publication Publication Date Title
JP2023501388A5 (https=)
US12559742B2 (en) Donor repair templates multiplex genome editing
JP6933898B2 (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
Papapetrou et al. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells
JP7422365B2 (ja) 外来抗原レセプター遺伝子導入細胞の製造方法
JP2024506751A (ja) 遺伝子サイレンシング
WO2017177137A1 (en) Chimeric antigen receptor t cell compositions
CN115551998A (zh) 低免疫原性细胞
JP2023532917A (ja) Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物
WO2022018884A1 (ja) 栄養障害型表皮水疱症の治療薬
WO2019173942A1 (en) Engineered chimeric guide rna and uses thereof
JP7807756B2 (ja) 所望の特異性を有するエフェクター細胞の製造方法
US20250270546A1 (en) Guide rnas and uses thereof
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
WO2026008633A1 (en) Intronic targeted insertion of transgenes
KR20220120428A (ko) Hla 유전자 편집에 의한 면역거절 항원이 없는 인간 유도만능줄기세포의 생산
Lee Genome Editing with Crispr/Cas9 to Study and Treat Primary Immune Regulatory Disorders
HK1233303B (en) Application of induced pluripotent stem cells to generate adoptive cell therapy products
HK1233303A1 (en) Application of induced pluripotent stem cells to generate adoptive cell therapy products
HK40013246B (zh) 用具有工程化穏定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法